Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million

ResMed has acquired Noctrix Health, a medical technology company specializing in wearable neuromodulation therapies for sleep and neurological conditions, for $340 million. This marks the first successful exit for Angelini Ventures, a corporate venture firm that invested in Noctrix during its $40 million Series C round in 2024. The acquisition will integrate Noctrix's FDA-authorized Nidra therapy for Restless Legs Syndrome into ResMed's broader sleep health ecosystem.

06/03/2026, 7:40 AM • Benzinga

9 Stocks That Could Defy the ’Sell in May and Go Away’ Trend This Time

Despite the traditional 'Sell in May and Go Away' market pattern, 2026 shows strong potential for continued stock gains. With 84% of companies beating earnings expectations and 27% earnings growth, selective investing in fundamentally strong companies could outperform. The article highlights two healthcare stocks—DexCom and ResMed—as well-positioned to deliver significant upside potential despite trading below analyst price targets.

05/05/2026, 1:04 PM • Investing

9 Stocks That Could Defy the ’Sell in May and Go Away’ Trend This Time

Despite the traditional 'Sell in May and Go Away' market pattern, 2026 shows strong potential for continued stock gains driven by exceptional earnings season (84% of companies beat expectations with 27% earnings growth). The article identifies 9 stocks with strong fundamentals and 30%+ upside potential, highlighting DexCom and ResMed as well-positioned healthcare companies that could outperform despite stretched valuations and geopolitical risks.

05/05/2026, 10:26 AM • Investing

9 Stocks That Could Defy the ’Sell in May and Go Away’ Trend This Time

Despite the traditional 'Sell in May and Go Away' market pattern, 2026 shows strong potential for continued gains with record highs, 84% of companies beating earnings expectations, and 27% earnings growth. The article identifies 9 stocks with over 30% upside potential and strong fundamentals as selective investment opportunities, though risks from global tensions, inflation, and stretched valuations remain.

05/05/2026, 7:22 AM • Investing

9 Stocks That Could Defy the ’Sell in May and Go Away’ Trend This Time

Despite the traditional 'Sell in May and Go Away' market pattern, 2026 presents a different outlook with the S&P 500 and NASDAQ starting May at record highs, driven by strong earnings season (84% beat expectations, 27% earnings growth). While risks remain from global tensions and stretched valuations, selective investing in fundamentally strong companies with analyst support could yield significant returns. Two highlighted stocks are DexCom and ResMed, both showing strong Q1/Q3 results and upside potential.

05/05/2026, 3:48 AM • Investing

Sleep Apnea Devices (Therapeutic, Diagnostic) Market Report 2026-2034 Featuring Key Players - ResMed, Koninklijke Philips, and Carefusion

The global sleep apnea devices market is expected to grow at a CAGR of 7.05% from 2025 to 2034, driven by rising prevalence of sleep apnea affecting approximately 1 billion people worldwide, increased obesity rates, and technological innovations in CPAP, BiPAP, and oral appliances. Growth is further supported by expanding homecare and telemedicine adoption. However, challenges include high device costs, limited access in developing regions, and poor patient compliance with therapy.

04/29/2026, 4:53 AM • GlobeNewswire

Global Respiratory Care Devices Market to Grow at a Substantial Growth Rate of ~8% by 2034 | DelveInsight

The global respiratory care devices market is projected to grow from USD 24.3 billion in 2025 to USD 47.5 billion by 2034, at a CAGR of ~8%. Growth is driven by rising prevalence of chronic respiratory diseases (COPD, asthma, sleep apnea), increasing demand for home healthcare solutions, technological advancements, and post-COVID-19 awareness. North America leads with 41% market share, followed by Europe and Asia-Pacific.

04/22/2026, 1:00 PM • GlobeNewswire

3 Reasons Not to Sleep on ResMed Stock

ResMed, a leader in CPAP machines and respiratory care devices, presents an attractive investment opportunity with 11% year-over-year revenue growth, expanding digital health capabilities across 140+ countries, and a forward P/E ratio of 22 (below its five-year average of 29). However, investors should be aware of potential headwinds including uncertain Medicare reimbursement rates and emerging alternative treatments.

03/10/2026, 2:30 PM • The Motley Fool

Anti-snoring Devices Market Competitive Landscape Report 2025: Top Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations and Launches, Sustainability Goals, Revenue Insights

The global anti-snoring devices market is expected to grow from $1.81 billion in 2025 to $3.36 billion by 2033, with an 8.04% CAGR. Growth drivers include rising obesity rates, increased awareness of health risks associated with snoring, technological innovations, and improved e-commerce accessibility. Major players like Philips, ResMed, and SomnoMed are leading the market with advanced solutions.

02/24/2026, 7:00 AM • GlobeNewswire

Analysts Maintain Bull Case On ResMed Despite Competition Concerns

ResMed reported strong Q2 FY2026 results with adjusted earnings of $2.81 beating consensus of $2.72, and sales of $1.42 billion up 11% YoY. The company received FDA clearance for its AI-enabled Smart Comfort device and expects high single-digit revenue growth with double-digit EPS growth. Most analysts maintain positive ratings despite competition concerns, though stock declined 2.33% on the day.

01/30/2026, 1:08 PM • Benzinga

Mechanical Ventilators Market Size to Reach USD 6.91 Billion by 2035, Driven by Rising Respiratory Disease Burden and Expanding Critical Care Infrastructure – SNS Insider

The global mechanical ventilators market is projected to grow from USD 4.04 billion in 2025 to USD 6.91 billion by 2035, expanding at a CAGR of 5.53%. Growth is driven by rising respiratory disease prevalence, expanding ICU infrastructure, and technological advancements including AI-enabled and portable ventilators. However, high device costs and limited healthcare funding remain significant market constraints.

01/29/2026, 6:00 AM • GlobeNewswire

Global Sleep Apnea Devices Market is Expected to Cross the USD 15 Billion Mark by 2032 | DelveInsight

The global sleep apnea devices market is projected to grow from USD 9.5 billion in 2024 to USD 15.8 billion by 2032, with a CAGR of approximately 6%. Growth is driven by rising OSA prevalence, technological advancements, increased awareness, and expanding healthcare infrastructure. North America leads the market with over 45% share, while Asia-Pacific emerges as a major growth driver. Key players include Philips, ResMed, and Fisher & Paykel Healthcare.

01/21/2026, 1:00 PM • GlobeNewswire

BVI Appoints Jim Hollingshead as President & Chief Executive Officer

BVI announced the appointment of Jim Hollingshead as President & CEO, succeeding Shervin Korangy. Hollingshead brings over 20 years of medical device experience from leadership roles at Insulet and ResMed. BVI has expanded its ophthalmic portfolio with FDA approvals for premium IOLs and new surgical platforms, positioning itself as a challenger in the eye surgery market.

01/19/2026, 9:00 AM • GlobeNewswire

Global Sleep Tech Devices Market Poised for Strong Growth at a CAGR of ~17% by 2032, Driven by Rising Sleep Disorder Prevalence | DelveInsight

The global sleep tech devices market is expected to grow from USD 17 billion in 2024 to USD 44 billion by 2032, driven by rising sleep disorder prevalence, increased awareness, and technological advancements. Wearables dominate with 69.69% revenue share, while North America leads regional growth. Key players include Philips, ResMed, Apple, Garmin, and Eight Sleep.

01/06/2026, 1:00 PM • GlobeNewswire

Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio

Nyxoah secured $77 million in financing through a private placement, registered direct offering, and convertible bond to support U.S. commercialization of its Genio system for treating Obstructive Sleep Apnea (OSA).

11/13/2025, 7:30 PM • GlobeNewswire